SoFi CEO enters prepaid forward contract on 1.5 million shares
In a recent SEC filing, Merus N.V. (NASDAQ:MRUS) disclosed that Harry Shuman, the company’s Vice President Controller and Principal Accounting Officer, sold a total of 4,000 common shares on March 21, 2025. The shares were sold at prices ranging from $48.48 to $48.55, amounting to a total transaction value of $193,990. According to InvestingPro data, the stock is currently trading near its Fair Value, with analysts setting price targets between $67 and $110.
The transactions included the sale of 3,000 shares at $48.48 each and an additional 1,000 shares at $48.55. Following these sales, Shuman’s direct ownership of Merus common shares stands at 11,002 shares.
Additionally, the filing reported the exercise of options, resulting in the acquisition of 3,000 common shares. These options were exercised at prices of $24.61 and $18.61 per share, with no immediate cash outlay reported for these transactions.
These transactions reflect Shuman’s ongoing engagement with Merus’s equity, as he manages his portfolio within the company.
In other recent news, Merus N.V. has been the focus of several analyst updates, reflecting significant developments in its clinical pipeline. Stifel has maintained a Buy rating with a $93 target, citing promising clinical data and strategic positioning in oncology, particularly for its drug candidate petosemtamab, which has received FDA Breakthrough Therapy Designation. H.C. Wainwright also reiterated a Buy rating with an $85 target, highlighting the ongoing Phase 3 trials for petosemtamab in head and neck squamous cell carcinoma (HNSCC) and the anticipated data updates in 2025. BMO Capital increased its price target to $96, maintaining an Outperform rating, due to narrowed timelines for petosemtamab’s clinical data and its role as a key value driver for the company.
Piper Sandler initiated coverage with an Overweight rating and an $84 target, emphasizing the potential of petosemtamab, particularly in combination therapies, and forecasting significant revenue potential by 2035. Meanwhile, Wells Fargo (NYSE:WFC) set a $91 target with an Overweight rating, pointing to the untapped potential of petosemtamab in metastatic colorectal cancer (mCRC) as a key growth opportunity. Analysts have expressed confidence in the forthcoming data and potential market applications of Merus’s drug candidates, suggesting a positive outlook for the company’s future performance in the oncology sector. These updates reflect a strong belief in Merus’s ability to leverage its clinical assets to meet unmet needs in cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.